aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

CEO

Dr. Sanjay S. Shukla M.D., M.S.

Employees

Country

ISIN

US0021202025

Listings

0 Comments

Share your thoughts

FAQ

What is Atyr Pharma stock price today?▼

The current price of ATYR is $0.85 USD — it has increased by +8.95% in the past 24 hours. Watch Atyr Pharma stock price performance more closely on the chart.

What is Atyr Pharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Atyr Pharma stocks are traded under the ticker ATYR.

Is Atyr Pharma stock price growing?▼

ATYR stock has risen by +6.03% compared to the previous week, the month change is a -11.7% fall, over the last year Atyr Pharma has showed a -70.57% decrease.

What is Atyr Pharma market cap?▼

Today Atyr Pharma has the market capitalization of 83.27M

When is the next Atyr Pharma earnings date?▼

Atyr Pharma is going to release the next earnings report on May 13, 2026.

What were Atyr Pharma earnings last quarter?▼

ATYR earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.18 USD resulting in a +23.81% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Atyr Pharma revenue for the last year?▼

Atyr Pharma revenue for the last year amounts to 470,000 USD.

What is Atyr Pharma net income for the last year?▼

ATYR net income for the last year is -128.05M USD.

How many employees does Atyr Pharma have?▼

As of April 01, 2026, the company has 56 employees.

In which sector is Atyr Pharma located?▼

Atyr Pharma operates in the Health Care sector.

When did Atyr Pharma complete a stock split?▼

The last stock split for Atyr Pharma was on July 01, 2019 with a ratio of 1:14.

Where is Atyr Pharma headquartered?▼

Atyr Pharma is headquartered in San Diego, US.